Subscribe to our newsletter

Alopecia Areata Registry

CorEvitas is now part of Thermo Fisher Scientific. Read More.

About Alopecia Areata

Alopecia Areata is an autoimmune disease caused by genetic and environmental factors, that result in non-scarring hair loss, as inflammatory pathways destroy hair follicles. It currently afflicts approximately two out of every 1,000 people in the U.S. and over 100 million people worldwide. Novel and effective therapies for Alopecia Areata offer patients the promise of effective treatment and relief from the burden of the disease, and a vastly improved quality of life.

About our Alopecia Areata Registry

The Alopecia Areata (AA) Registry, is a prospective, observational cohort study for subjects with AA under the care of a dermatology provider. A first of its kind in Alopecia Areata, the registry is designed to study the natural history of AA, the real-world effectiveness and safety of medications used in the treatment of AA, and drug utilization treatment patterns.

Structured clinical data are collected approximately every 6 months at regular office visits from patients and providers at the time of routine clinical encounters.

Read the Press Release, here.

Registry Scientific Advisors

Picture of Brett King, MD, PhD

Brett King, MD, PhD

Associate Professor of Dermatology, Yale University School of Medicine | Clinician, Yale Dermatology-Middlebury

Picture of Maryanne Senna, MD

Maryanne Senna, MD

Assistant Professor of Dermatology Harvard Medical School | Director, Lahey Hair Loss Center of Excellence & Hair Academic Innovative Research Unit, Beth Israel Lahey Health | Board of directors, Cicatricial Alopecia Research Foundation and American Hair Research Society